Dr. Michael Ortiz, MD
Claim this profileMemorial Sloan Kettering Cancer Center
Area of expertise
Solid Tumors
Michael Ortiz, MD has run 3 trials for Solid Tumors. Some of their research focus areas include:
Hepatoblastoma
Michael Ortiz, MD has run 2 trials for Hepatoblastoma. Some of their research focus areas include:
Affiliated Hospitals
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering At Basking Ridge (Limited Protocol Activities)
Clinical Trials Michael Ortiz, MD is currently running
Chemotherapy
for Wilms Tumor
This phase II trial studies how well combination chemotherapy works in treating patients with newly diagnosed stage II-IV diffuse anaplastic Wilms tumors (DAWT) or favorable histology Wilms tumors (FHWT) that have come back (relapsed). Drugs used in chemotherapy regimens such as UH-3 (vincristine, doxorubicin, cyclophosphamide, carboplatin, etoposide, and irinotecan) and ICE/Cyclo/Topo (ifosfamide, carboplatin, etoposide, cyclophosphamide, and topotecan) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. This trial may help doctors find out what effects, good and/or bad, regimen UH-3 has on patients with newly diagnosed DAWT and standard risk relapsed FHWT (those treated with only 2 drugs for the initial WT) and regimen ICE/Cyclo/Topo has on patients with high and very high risk relapsed FHWT (those treated with 3 or more drugs for the initial WT).
Recruiting
1 award
Phase 2
12 criteria
Codrituzumab
for Solid Tumors
This trial is testing codrituzumab, a medicine that targets a specific protein on cancer cells, in children and young adults with certain types of tumors. The goal is to see if it is safe and has few side effects.
Recruiting
1 award
Phase 1
More about Michael Ortiz, MD
Clinical Trial Related
7 years of experience running clinical trials · Led 6 trials as a Principal Investigator · 3 Active Clinical Trials
Treatments Michael Ortiz, MD has experience with
- Codrituzumab
- Selinexor
- Carboplatin
- Cyclophosphamide
- Doxorubicin
- Etoposide
Breakdown of trials Michael Ortiz, MD has run
Simpson-Golabi-Behmel syndrome
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Michael Ortiz, MD specialize in?
Michael Ortiz, MD focuses on Solid Tumors and Hepatoblastoma. In particular, much of their work with Solid Tumors has involved GPC3 positive patients, or patients who are Stage IV.
Is Michael Ortiz, MD currently recruiting for clinical trials?
Yes, Michael Ortiz, MD is currently recruiting for 3 clinical trials in New York New York. If you're interested in participating, you should apply.
Are there any treatments that Michael Ortiz, MD has studied deeply?
Yes, Michael Ortiz, MD has studied treatments such as Codrituzumab, Selinexor, Carboplatin.
What is the best way to schedule an appointment with Michael Ortiz, MD?
Apply for one of the trials that Michael Ortiz, MD is conducting.
What is the office address of Michael Ortiz, MD?
The office of Michael Ortiz, MD is located at: Memorial Sloan Kettering Cancer Center, New York, New York 10065 United States. This is the address for their practice at the Memorial Sloan Kettering Cancer Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.